---
company: HEALTHPEAK PROPERTIES, INC.
ticker: DOC
form: 8-K
filed: 2026-05-05
accession: 0001628280-26-030561
source: https://www.sec.gov/Archives/edgar/data/765880/000162828026030561/
---

# Healthpeak Properties (DOC) earnings release, May 5, 2026

Healthpeak Properties, Inc. (DOC) · Form 8-K, Item 2.02 · Filed 2026-05-05 · [SEC filing](https://www.sec.gov/Archives/edgar/data/765880/000162828026030561/)

Healthpeak Properties Raises 2026 Earnings Guidance Following Completion of the Janus Living IPO, Accretive Capital Allocation, and Strong First Quarter 2026 Results

DENVER, May 5, 2026 -

Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended March 31, 2026.

FIRST QUARTER 2026 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.28 per share, Nareit FFO of $0.42 per share, and FFO as Adjusted of $0.45 per share – In March 2026, Janus Living, Inc. (NYSE: JAN) ("Janus Living") completed its initial public offering ("IPO") at the high-end of the valuation range, generating approximately $880 million of net proceeds in an oversubscribed and upsized offering, to pursue accretive acquisition and investment opportunities

• As Janus Living's largest shareholder, Healthpeak's earnings growth will benefit from the favorable senior housing supply-demand fundamentals and Janus Living's accretive external growth opportunities

• $714 million of previously disclosed Healthpeak senior housing acquisitions contributed to Janus Living as part of the formation transactions

• Janus Living reported it is under contract on an additional $400 million of senior housing acquisitions

• As of May 4, 2026, Janus Living had a market capitalization of $6.9 billion, of which Healthpeak owns 81.6% – Janus Living reported post-IPO net loss of $(0.05) per share, first quarter net income of $0.13 per share and first quarter FFO as Adjusted of $0.23 per share

• Year-over-year consolidated revenue and Adjusted EBITDAre growth of 35% and 42%, respectively – First quarter Outpatient Medical and Lab new and renewal lease executions totaled 1.2 million square feet:

• Outpatient Medical new lease executions totaled 195,000 square feet and renewal lease executions totaled 868,000 square feet, with +5.4% cash releasing spreads on renewals

◦ Subsequent to the first quarter, and through May 4, 2026, executed 1 million square feet of Outpatient Medical leases and signed letters of intent ("LOI")

• Lab new lease executions totaled 129,000 square feet and renewal lease executions totaled 12,000 square feet and +3.5% cash releasing spreads on renewals

◦ Subsequent to the first quarter, and through May 4, 2026, executed 354,000 square feet of Lab leases and signed LOIs – Lab total occupancy increased sequentially and is expected to increase through year-end 2026 – Generated $267 million of proceeds from recapitalizations, dispositions, and loan repayments

• In March 2026, closed on the recapitalization and sale of an 80% joint venture interest in a 100% occupied, six-property outpatient medical portfolio to affiliates of Blackstone at a gross valuation of $212 million, generating proceeds of approximately $170 million – In April 2026, repurchased 5.9 million common shares at a weighted average share price of $16.81 for approximately $100 million – Net Debt to Adjusted EBITDAre was 5.4x for the quarter ended March 31, 2026 – Recent corporate impact and sustainability achievements include:

• Awarded LEED Silver Core & Shell for Medical City McKinney, an outpatient medical development located in suburban Dallas

• Named a member of the Dow Jones Best-in-Class (DJBIC) North America Index for the 13 th consecutive year

• Named a constituent in the S&P Global Sustainability Yearbook for the 11 th consecutive year

Page 1

To learn more about Healthpeak's commitment to responsible business and view our Corporate Impact Report, please visit www.healthpeak.com/corporate-impact.

FIRST QUARTER COMPARISON

SAME-STORE ("SS") OPERATING SUMMARY

The table below outlines the year-over-year three-month total SS Cash (Adjusted) NOI growth.

Nareit FFO, FFO as Adjusted, Total Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts. See "March 31, 2026 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP, available in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results. See also the "Funds From Operations" section of this release for additional information.

Page 2

DIVIDEND

On April 6, 2026, Healthpeak's Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of April, May, and June of 2026, representing cash dividends totaling $0.305 per share for the second quarter, and an annualized dividend amount of $1.22 per share. The dividend is payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date.

JANUS LIVING INITIAL PUBLIC OFFERING

In March 2026, Janus Living completed its IPO and began trading on the New York Stock Exchange under the ticker symbol “JAN”. The net proceeds from the IPO were approximately $880 million, after deducting underwriting discounts and expenses payable by Janus Living.

Janus Living expects to use the net proceeds from the offering to pursue acquisition and investment opportunities that meet its investment criteria and for general corporate purposes.

As of the IPO, Healthpeak owned approximately 214.7 million shares of common stock and operating partnership common units in Janus Living, representing an 81.6% equity ownership.

JANUS LIVING'S FIRST QUARTER RESULTS... (truncated)approximately $400 million of incremental senior housing acquisitions. As of March 31, 2026, Janus Living had $949 million of cash and no outstanding debt.

Janus Living also announced its intent to make a pro rata dividend payment for the period between March 20, 2026 and June 30, 2026, based on a distribution rate of $0.1425 per share, representing an annualized dividend of $0.57 per share.

Janus Living’s operations are consolidated into Healthpeak’s financial statements, with the approximately 18.4% not owned by Healthpeak reported as noncontrolling interest.

SENIOR HOUSING ACQUISITIONS

During the first quarter 2026, Healthpeak closed on senior housing acquisitions totaling $714 million across 25 communities. These communities were contributed to Janus Living as part of the formation transactions.

A summary of the acquisitions is as follows:

• Our joint venture partner's 46.5% interest in a 19-community portfolio for $314 million

• Three communities in the Orlando MSA for $119 million

• Two communities in the Atlanta MSA for $240 million

• One community in the Seattle MSA for $41 million

SHARE REPURCHASE ACTIVITY

In April 2026, Healthpeak repurchased 5.9 million common shares at a weighted average share price of $16.81 for approximately $100 million under its $500 million share repurchase program.

As of May 5, 2026, approximately $306 million remained available for share repurchases under the program.

OUTPATIENT MEDICAL JOINT VENTURE RECAPITALIZATION

In March 2026, Healthpeak entered into a joint venture with affiliates of Blackstone through the contribution of a 100% occupied, six-property outpatient medical portfolio valued at approximately $212 million. The portfolio comprises approximately 418,000 square feet across California, Maryland, Colorado, Texas, and Nebraska.

Under the terms of the joint venture, Blackstone owns an 80% majority interest and Healthpeak retains a 20% minority interest. Healthpeak will serve as operating member of the joint venture and will continue to provide asset and property management services, earning customary fees. The joint venture establishes a platform from which the parties will seek to expand their relationship over time. Healthpeak received gross proceeds of approximately $170 million for the sale of the 80% interest. The transaction implies a trailing cash cap rate of approximately 6.1%

Page 3 and a valuation of approximately $508 per square foot. The transaction reflects continued execution on Healthpeak’s ongoing capital recycling strategy and the strong private market interest in Healthpeak's operating platform and relationships.

DISPOSITIONS

During the first quarter 2026, Healthpeak closed on approximately $92 million of dispositions and received loan repayments for proceeds of $5 million. Together with the recapitalization, Healthpeak has generated $267 million of net proceeds as of May 5, 2026.

## Financial statements

### Income Statement (Three Months Ended March 31, — In thousands, except per share data)

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Revenues: | Rental and related revenues | 538,436 | 538,141 |
| Revenues: | Resident fees and services | 200,345 | 148,927 |
| Revenues: | Interest income and other | 14,171 | 15,821 |
| Revenues: | Total revenues | 752,952 | 702,889 |
| Costs and expenses: | Operating | 323,861 | 273,143 |
| Costs and expenses: | Depreciation and amortization | 289,734 | 268,546 |
| Costs and expenses: | Interest expense | 87,292 | 72,693 |
| Costs and expenses: | General and administrative | 24,591 | 26,118 |
| Costs and expenses: | Transaction costs | 24,149 | 5,534 |
| Costs and expenses: | Impairments and loan loss reserves (recoveries), net | -2,275 | -3,562 |
| Costs and expenses: | Total costs and expenses | 747,352 | 642,472 |
| Other income (expense): | Gain (loss) on sales of real estate, net | 50,669 |  |
| Other income (expense): | Gain (loss) on debt extinguishments | -403 |  |
| Other income (expense): | Other income (expense), net | 139,779 | -6,126 |
| Other income (expense): | Total other income (expense), net | 190,045 | -6,126 |
| Other income (expense): | Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 195,645 | 54,291 |
| Other income (expense): | Income tax benefit (expense) | -254 | -2,080 |
| Other income (expense): | Equity income (loss) from unconsolidated joint ventures | 4,265 | -2,147 |
| Other income (expense): | Net income (loss) | 199,656 | 50,064 |
| Other income (expense): | Noncontrolling interests’ share in earnings | -6,023 | -7,236 |
| Other income (expense): | Net income (loss) attributable to Healthpeak Properties, Inc. | 193,633 | 42,828 |
| Other income (expense): | Participating securities’ share in earnings | -149 | -464 |
| Other income (expense): | Net income (loss) applicable to common shares | 193,484 | 42,364 |
| Earnings per common share: | Basic | 0.28 | 0.06 |
| Earnings per common share: | Diluted | 0.28 | 0.06 |
| Weighted average shares outstanding: | Basic | 695,161 | 699,067 |
| Weighted average shares outstanding: | Diluted | 695,168 | 699,118 |

### Income Statement (Three Months Ended March 31, — In thousands, except per share data)

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Net income (loss) applicable to common shares | 193,484 | 42,364 |
| Real estate related depreciation and amortization | 289,734 | 268,546 |
| Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures | 7,212 | 12,200 |
| Noncontrolling interests’ share of real estate related depreciation and amortization | -4,702 | -4,454 |
| Loss (gain) on sales of depreciable real estate, net | -50,669 |  |
| Loss (gain) upon change of control, net(1) | -138,117 |  |
| Taxes associated with real estate dispositions | 58 |  |
| Nareit FFO applicable to common shares | 297,000 | 318,656 |
| Distributions on dilutive convertible units and other | 4,519 | 4,623 |
| Diluted Nareit FFO applicable to common shares | 301,519 | 323,279 |
| Diluted Nareit FFO per common share | 0.42 | 0.45 |
| Weighted average shares outstanding - Diluted Nareit FFO | 709,457 | 714,174 |
| Impact of adjustments to Nareit FFO: | Transaction, merger, and restructuring-related costs(2) | 20,568 | 5,534 |
| Impact of adjustments to Nareit FFO: | Other impairments (recoveries) and other losses (gains), net(3) | -2,275 | -3,320 |
| Impact of adjustments to Nareit FFO: | Loss (gain) on debt extinguishments | 302 |  |
| Impact of adjustments to Nareit FFO: | Casualty-related charges (recoveries), net(4) | -190 | 4,226 |
| Impact of adjustments to Nareit FFO: | Recognition (reversal) of valuation allowance on deferred tax assets(5) | -3,058 |  |
| Impact of adjustments to Nareit FFO: | Total adjustments | 15,347 | 6,440 |
| Impact of adjustments to Nareit FFO: | FFO as Adjusted applicable to common shares | 312,347 | 325,096 |
| Impact of adjustments to Nareit FFO: | Distributions on dilutive convertible units and other | 4,506 | 4,617 |
| Impact of adjustments to Nareit FFO: | Diluted FFO as Adjusted applicable to common shares | 316,853 | 329,713 |
| Impact of adjustments to Nareit FFO: | Diluted FFO as Adjusted per common share | 0.45 | 0.46 |
| Impact of adjustments to Nareit FFO: | Weighted average shares outstanding - Diluted FFO as Adjusted | 709,457 | 714,174 |
| Other operating data: | Amortization of deferred financing costs and debt discounts (premiums) | 8,363 | 7,852 |
| Other operating data: | Non-refundable entrance fee sales in excess of (less than) the related GAAP amortization | 7,756 | 4,696 |
| Other operating data: | Stock-based compensation amortization expense | 4,502 | 4,627 |
| Other operating data: | Deferred income taxes | 3,053 | 2,570 |
| Other operating data: | AFFO capital expenditures | -23,956 | -23,136 |
| Other operating data: | Straight-line rents | -10,905 | -11,153 |
| Other operating data: | Amortization of above (below) market lease intangibles, net | -6,597 | -10,212 |
| Other operating data: | Other items(6) | -2,606 | 1,451 |

### Balance Sheet (In thousands, except share and per share data)

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Real estate: | Buildings and improvements | 17,168,415 | 16,593,535 |
| Real estate: | Development costs and construction in progress | 1,056,909 | 1,010,657 |
| Real estate: | Land and improvements | 3,221,127 | 3,007,346 |
| Real estate: | Accumulated depreciation | -4,609,647 | -4,512,443 |
| Real estate: | Net real estate | 16,836,804 | 16,099,095 |
| Real estate: | Loans receivable, net of reserves of $9,290 and $11,345 | 631,648 | 606,020 |
| Real estate: | Investments in unconsolidated joint ventures | 530,354 | 802,601 |
| Real estate: | Accounts receivable, net of allowance of $3,480 and $2,018 | 91,467 | 78,327 |
| Real estate: | Cash and cash equivalents | 1,170,992 | 467,457 |
| Real estate: | Restricted cash | 94,917 | 70,245 |
| Real estate: | Intangible assets | 758,495 | 654,516 |
| Real estate: | Assets held for sale | 45,667 | 80,621 |
| Real estate: | Right-of-use asset | 395,929 | 412,198 |
